Vectans Pharma
Vectans Pharma is a French specialty pharmaceutical company that develops and licenses muco-adhesive buccal tablet medicines (Lauriad® Aciclovir and Lauriad® Miconazole) for herpes labialis and oropharyngeal candidiasis, commercializing them globally through regional licensing partners.
- Company typePrivate
- Founded2015
- HeadquartersSaint-cloud, France
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Vectans Pharma does
Vectans Pharma SAS is a privately held French pharmaceutical company headquartered in Saint-Cloud, France, that develops and commercializes medicines based on its proprietary Lauriad® muco-adhesive buccal tablet technology. The Lauriad® platform is built on a novel natural biodegradable polymer derived from milk protein concentrate combined with hypromellose, enabling rapid bioadhesion to the gingival mucosa and sustained drug release for over 12 hours at the site of disease while avoiding first-pass hepatic metabolism and gastrointestinal enzymatic degradation. Two products are commercialized from this platform: Lauriad® Aciclovir (marketed as Sitavig®, Virpax®, Herpmed®, Virono® and Labiriad® in different countries) for recurrent herpes labialis, and Lauriad® Miconazole (marketed as Loramyc®, Oravig® and Oravi®) for oropharyngeal candidiasis in immunocompromised patients. Both products have received regulatory approvals across major markets including the US FDA, PMDA (Japan), NMPA (China), EU agencies, AIFA (Italy), ANSM (France), and MFDS (South Korea), and Lauriad® Aciclovir has gained OTC status in four European countries.
The company operates a licensing-and-distribution business model and does not sell directly to patients or pharmacies. Instead, Vectans Pharma secures regulatory approvals and grants commercialization rights to regional pharmaceutical partners who handle local registration, distribution, and sales, generating revenue through licensing and royalties. Its partner network spans Asia, Europe, the Americas, and Africa and includes Zambon, Menarini, Daewoong, Berlin Chemie, Navamedic, Instituto Gentili, Moksha8, Hisamitsu Pharmaceutical, Galt, SciClone, Therabel, Celnova, and others. The company maintains an 11-50 employee organization led by co-founder and CEO Jérôme Théron, with a full executive committee (COO, CMO, CCO, CITO) and a supervisory board. In September 2025, Subtipharm and Athena Pharmaceutiques acquired a controlling interest in Vectans Pharma to drive global growth and reinforce business development worldwide, marking a structural change in ownership while the company continues to pursue platform-level R&D and new geographic launches (e.g., Argentina via Celnova).
Vectans Pharma firmographics
Firmographics- Name
- Vectans Pharma
- Legal name
- Vectans Pharma SAS
- Website
- https://vectanspharma.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Vectans Pharma is a French specialty pharmaceutical company that develops and licenses muco-adhesive buccal tablet medicines (Lauriad® Aciclovir and Lauriad® Miconazole) for herpes labialis and oropharyngeal candidiasis, commercializing them globally through regional licensing partners.
- Ownership category
- akta.pro rank
Vectans Pharma industry classification
Industry- Product category
- Specialty Pharmaceuticals (Muco-adhesive Drug Delivery)
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)
- akta.pro secondary industry
- Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD)
Keywords
Where Vectans Pharma is headquartered
LocationHeadquarters
- HQ city
- Saint-cloud
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
Vectans Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Pharmaceutical product sales via licensing and distribution partnerships: Vectans Pharma develops and commercializes pharmaceutical products through licensing and distribution agreements with regional pharmaceutical partners. The company retains rights to its technology platform while granting commercialization rights to partners in specific geographies. Revenue is generated through product sales under brand names including Virpax®, Sitavig®, Herpmed®, Virono®, Loramyc®, Oravig®, and Oravi® across multiple countries.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Vectans Pharma product offering
Product offeringCore offering
Vectans Pharma develops and commercializes pharmaceutical products built on its proprietary Lauriad® muco-adhesive buccal tablet drug delivery platform. The company currently markets two active treatments: Lauriad® Aciclovir 50mg for recurrent herpes labialis and Lauriad® Miconazole 50mg for oropharyngeal candidiasis. Products are distributed globally through licensing agreements and commercial/industrial pharmaceutical partners across Asia, Europe, and the Americas.
Product overview
Vectans Pharma is an innovative pharmaceutical company offering a portfolio of "best-in-disease" treatments based on its proprietary Lauriad® Technology Platform. The platform is a muco-adhesive buccal tablet capable of sustained drug release for over 12 hours, enabling targeted local delivery of active pharmaceutical ingredients. The company commercializes two core products: LAURIAD® ACICLOVIR (marketed as Sitavig®, Virpax®, Herpmed®, Virono®, Labiriad® regionally) for herpes labialis treatment, and LAURIAD® MICONAZOLE (marketed as Loramyc®, Oravig®, Oravi® regionally) for oropharyngeal candidiasis treatment. These products are distributed globally through commercial partnerships across Asia, Europe, and Americas. Vectans Pharma ensures all phases of product development from R&D to marketing.
Differentiator
Problem solved
Functional benefit
Products and services
- Lauriad® Aciclovir 50mg (Sitavig®/Virpax®/Herpmed®/Virono®/Labiriad®) 50mg muco-adhesive buccal tablet for the treatment of recurrent herpes labialis (cold sores). Approved by the US FDA, AIFA (Italy), ANSM (France), MFDS (South Korea), and other authorities. Marketed as a single-application treatment providing up to 24-hour sustained acyclovir exposure in saliva and oral mucosa. Available as prescription and OTC in multiple countries.
- Lauriad® Miconazole 50mg (Loramyc®/Oravig®/Oravi®) 50mg muco-adhesive buccal tablet for the treatment of oropharyngeal candidiasis in immunocompromised patients. Approved by the US FDA, PMDA (Japan), NMPA (China), and EU agencies. Achieves therapeutic efficacy with a 10-fold lower miconazole dose (50mg) compared to conventional topical gel (500mg), administered once daily instead of four times daily.
Quantifiable outcome
- A single application of acyclovir muco-adhesive buccal tablet resulted in high exposure of acyclovir to saliva and oral mucosa sustained for 24 hours vs. oral acyclovir requiring frequent dosing due to low bioavailability.
- +3 more outcomes
Companies that use Vectans Pharma
Customer profileSegments2 records
Ideal customer profiles2 records
Vectans Pharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Vectans Pharma partnerships and signals
Strategic signalPartnerships
19 partnerships are on record, tiered regional, core and minor.
- Navamedic ASAregionalNavamedic ASA is Vectans Pharma's partner in Sweden for Virono® 50mg, the OTC version of Lauriad® Aciclovir. The Swedish Medical Products Agency granted OTC status to this product through the partnership with Navamedic.
- ZamboncoreZambon and Vectans Pharma entered into a partnership to commercialize Virpax®, Lauriad® Aciclovir 50mg, in France. Zambon handles the marketing and sales of the product in the French market.
- CelnovaregionalCelnova and Vectans Pharma signed an exclusive licensing agreement for commercialization of Loramyc® 50mg (Lauriad® Miconazole) in Argentina for the treatment of oropharyngeal candidiasis. Next step is the Marketing Authorization (MA) submission.
- Menarini GroupregionalMenarini Group commercializes Herpmed® 50mg (Lauriad® Aciclovir) in Italy. Listed as a commercial and industrial partner of Vectans Pharma.
- DaewoongregionalDaewoong commercializes Sitavig® 50mg (Lauriad® Aciclovir) in South Korea. Listed as a commercial and industrial partner of Vectans Pharma.
- Berlin ChemieregionalBerlin Chemie has an agreement with Vectans Pharma for Sitavig® (Lauriad® Aciclovir). Listed as a commercial partner on the Vectans Pharma partners page.
- Instituto GentiliregionalInstituto Gentili commercializes Loramyc® 50mg in Italy. Listed as a commercial and industrial partner of Vectans Pharma.
- Moksha8regionalMoksha8 commercializes Loramyc® 50mg in Mexico. Listed as a commercial and industrial partner of Vectans Pharma.
- Hisamitsu PharmaceuticalregionalHisamitsu Pharmaceutical commercializes Oravi® 50mg (Lauriad® Miconazole) in Japan. Listed as a commercial and industrial partner of Vectans Pharma.
- GaltregionalGalt commercializes Oravig® 50mg (Lauriad® Miconazole) in the USA. Listed as a commercial and industrial partner of Vectans Pharma.
- SciCloneregionalSciClone commercializes Loramyc® 50mg (Lauriad® Miconazole) in China. Listed as a commercial and industrial partner of Vectans Pharma.
- TherabelregionalTherabel commercializes Loramyc® 50mg in France. Listed as a commercial and industrial partner of Vectans Pharma.
- FarevaminorFareva is listed as a commercial and industrial partner of Vectans Pharma on the partnership page.
- CatalentminorCatalent is listed as a commercial and industrial partner of Vectans Pharma on the partnership page.
- Sosei HeptaresminorSosei Heptares is listed as a commercial and industrial partner of Vectans Pharma on the partnership page.
- Gen-OrphminorGen-Orph is listed as a commercial and industrial partner of Vectans Pharma on the partnership page.
- NC pharmaminorNC pharma (Brazil) is listed as a commercial and industrial partner of Vectans Pharma on the partnership page.
- LigandminorLigand is listed as a commercial and industrial partner of Vectans Pharma on the partnership page.
- Academic and research institutionsminorVectans Pharma collaborates with academic researchers, biotechnology research teams, and other pharmaceutical companies for R&D. The company states that collaborations with external partners are essential to their R&D efforts and they continuously seek new partnerships with leading experts and research teams.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
Vectans Pharma competitors and assessment
Company assessmentOthers
- Catalent: Global contract development and manufacturing organization (CDMO) supporting pharmaceutical drug delivery and clinical/commercial supply. Comparable as a listed partner on Vectans' commercial/industrial partner page and as an enabling service provider to buccal/drug delivery specialists.
Emerging players
- Ligand Pharmaceuticals: US-based platform pharma that develops and licenses drug delivery/technology platforms (e.g., Captisol®) to commercial partners for royalty streams. Comparable to Vectans in platform-and-royalty business model, though operating at much larger scale.
- Apricus Biosciences: Specialty drug delivery company historically focused on topical/transdermal product development and out-licensing (e.g., Vitaros®). Comparable to Vectans in the small-cap, delivery-platform-driven, partner-licensed specialty pharma archetype.
Broad incumbents
- Norgine: European specialty pharma commercializing differentiated Rx and OTC products through partner networks across multiple European and international markets. Comparable to Vectans in distribution-led, partner-driven commercialization of niche therapeutic products.
- Zambon: Italian-headquartered specialty pharma focused on respiratory, pain, and women's health, commercializing products through proprietary channels in major European markets. Comparable as Vectans' Virpax® distribution partner in France and as a peer European specialty pharma.
- Menarini Group: Large Italian specialty pharma commercializing branded Rx and consumer health products across Europe and emerging markets via its own sales force. Comparable as Vectans' Italian distributor for Herpmed® and as a peer in partner-driven European specialty pharma distribution.
- Hisamitsu Pharmaceutical: Japanese specialty pharma with a portfolio of transdermal/muco-adhesive drug delivery products (e.g., Salonpas® patches). Comparable to Vectans as both a Lauriad® Aciclovir commercial partner in Japan and as an incumbent in adhesive drug delivery technologies.
Regional players
- SciClone Pharmaceuticals: US-headquartered specialty pharma commercializing therapeutics in China and other Asian markets through partnership-led models. Comparable as Vectans' Loramyc® distribution partner in China and as a peer in China-focused specialty pharma commercialization.
Direct peers
- BioDelivery Sciences International (BDSI / Collegium): Specialty pharma focused on novel buccal/muco-adhesive and abuse-deterrent drug delivery platforms (e.g., BEMA® film technology). Highly comparable in business model: small-cap specialty drug delivery company commercializing differentiated formulations of established molecules via licensing/partners.
- ONXEO (formerly BioAlliance Pharma): Direct predecessor and originator of the Lauriad® muco-adhesive buccal technology. ONXEO is a French specialty oncology/infectious-disease pharma that previously developed and commercialized the same Loramyc®/Sitavig® assets now controlled by Vectans, making it the closest historical and product-overlap peer.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
Vectans Pharma social profiles
Digital presenceVectans Pharma compliance and trust
Trust signalCompliance2 records
Vectans Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Vectans Pharma leadership team
Management profileNumber of profiles
Profiles9 records
Vectans Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Vectans Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Vectans Pharma
What does Vectans Pharma do?
Vectans Pharma develops and commercializes pharmaceutical products built on its proprietary Lauriad® muco-adhesive buccal tablet drug delivery platform. The company currently markets two active treatments: Lauriad® Aciclovir 50mg for recurrent herpes labialis and Lauriad® Miconazole 50mg for oropharyngeal candidiasis. Products are distributed globally through licensing agreements and commercial/industrial pharmaceutical partners across Asia, Europe, and the Americas.
Is Vectans Pharma a public or private company?
Vectans Pharma is a private company. It is classified as corporate owned and is currently operating.
When was Vectans Pharma founded?
Vectans Pharma was founded in 2015. It employs 11 to 50 people.
Where is Vectans Pharma based?
Vectans Pharma is headquartered in Saint-cloud, France, in the Europe region.
How does Vectans Pharma make money?
One revenue line is on record: pharmaceutical product sales via licensing and distribution partnerships.
Who are Vectans Pharma's main competitors?
Catalent is listed as an others. Emerging players are Ligand Pharmaceuticals and Apricus Biosciences. Broad incumbents are Norgine, Zambon, Menarini Group and Hisamitsu Pharmaceutical. SciClone Pharmaceuticals is listed as a regional player. Direct peers are BioDelivery Sciences International (BDSI / Collegium) and ONXEO (formerly BioAlliance Pharma).
Does Vectans Pharma have an API?
No public API is recorded for Vectans Pharma.
What industry is Vectans Pharma in?
Vectans Pharma's product category is Specialty Pharmaceuticals (Muco-adhesive Drug Delivery). Its primary akta.pro industry code is HLAIAAAN, Pain Management & Anesthesiology Pharmaceuticals, with a secondary code of CRADAMAD, Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges). Its NAICS code is 325412 and its SIC code is 2834.